La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !
Rhinomed Résultats passés
Passé contrôle des critères 0/6
Rhinomed's earnings have been declining at an average annual rate of -8.2%, while the Pharmaceuticals industry saw earnings growing at 35.6% annually. Revenues have been growing at an average rate of 27.6% per year.
Informations clés
-8.2%
Taux de croissance des bénéfices
12.2%
Taux de croissance du BPA
Pharmaceuticals Croissance de l'industrie | 31.2% |
Taux de croissance des recettes | 27.6% |
Rendement des fonds propres | n/a |
Marge nette | -135.5% |
Dernière mise à jour des bénéfices | 30 Jun 2023 |
Mises à jour récentes des performances passées
Recent updates
Rhinomed Limited's (ASX:RNO) CEO Will Probably Find It Hard To See A Huge Raise This Year
Nov 10Is Rhinomed (ASX:RNO) Using Too Much Debt?
Mar 03Rhinomed (ASX:RNO) Is In A Strong Position To Grow Its Business
Mar 01Here's Why We're Not Too Worried About Rhinomed's (ASX:RNO) Cash Burn Situation
Jul 09Here's Why We're Watching Rhinomed's (ASX:RNO) Cash Burn Situation
Mar 01Key Things To Understand About Rhinomed's (ASX:RNO) CEO Pay Cheque
Jan 25How Many Rhinomed Limited (ASX:RNO) Shares Did Insiders Buy, In The Last Year?
Dec 20Ventilation des recettes et des dépenses
Comment Rhinomed gagne et dépense de l'argent. Sur la base des derniers bénéfices déclarés, sur une base LTM.
Historique des gains et des recettes
Date | Recettes | Les revenus | Dépenses G+A | Dépenses de R&D |
---|---|---|---|---|
30 Jun 23 | 8 | -11 | 12 | 1 |
31 Mar 23 | 9 | -9 | 11 | 1 |
31 Dec 22 | 9 | -7 | 11 | 2 |
30 Sep 22 | 10 | -6 | 10 | 2 |
30 Jun 22 | 10 | -5 | 10 | 2 |
31 Mar 22 | 8 | -6 | 10 | 1 |
31 Dec 21 | 6 | -6 | 9 | 1 |
30 Sep 21 | 5 | -8 | 10 | 1 |
30 Jun 21 | 4 | -9 | 10 | 1 |
31 Mar 21 | 5 | -8 | 10 | 1 |
31 Dec 20 | 5 | -7 | 9 | 0 |
30 Sep 20 | 5 | -7 | 9 | 0 |
30 Jun 20 | 4 | -7 | 9 | 0 |
31 Mar 20 | 4 | -8 | 9 | 0 |
31 Dec 19 | 4 | -8 | 9 | 0 |
30 Sep 19 | 4 | -7 | 8 | 0 |
30 Jun 19 | 3 | -6 | 7 | 0 |
31 Mar 19 | 3 | -5 | 6 | 0 |
31 Dec 18 | 3 | -5 | 6 | 0 |
30 Sep 18 | 3 | -5 | 5 | 0 |
30 Jun 18 | 2 | -4 | 5 | 0 |
31 Mar 18 | 2 | -4 | 5 | 0 |
31 Dec 17 | 1 | -5 | 5 | 0 |
30 Sep 17 | 2 | -5 | 5 | 0 |
30 Jun 17 | 2 | -4 | 5 | 0 |
31 Mar 17 | 2 | -5 | 5 | 0 |
31 Dec 16 | 2 | -5 | 5 | 0 |
30 Sep 16 | 1 | -5 | 5 | 0 |
30 Jun 16 | 1 | -6 | 6 | 0 |
31 Mar 16 | 1 | -6 | 5 | 0 |
31 Dec 15 | 1 | -6 | 5 | 1 |
30 Sep 15 | 1 | -6 | 5 | 1 |
30 Jun 15 | 0 | -5 | 4 | 1 |
31 Mar 15 | 0 | -5 | 3 | 1 |
31 Dec 14 | 0 | -5 | 2 | 0 |
30 Sep 14 | 0 | -4 | 1 | 0 |
30 Jun 14 | 0 | -4 | 1 | 0 |
31 Mar 14 | 0 | -4 | 0 | 0 |
31 Dec 13 | 0 | -4 | 2 | 0 |
30 Sep 13 | 0 | -9 | 2 | 0 |
30 Jun 13 | 0 | -15 | 2 | 0 |
Des revenus de qualité: RNO is currently unprofitable.
Augmentation de la marge bénéficiaire: RNO is currently unprofitable.
Analyse des flux de trésorerie disponibles par rapport aux bénéfices
Analyse de la croissance passée des bénéfices
Tendance des revenus: RNO is unprofitable, and losses have increased over the past 5 years at a rate of 8.2% per year.
Accélération de la croissance: Unable to compare RNO's earnings growth over the past year to its 5-year average as it is currently unprofitable
Bénéfices par rapport au secteur d'activité: RNO is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (28.2%).
Rendement des fonds propres
ROE élevé: RNO's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.